INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Baxter International, Inc. of Class Action Lawsuit and Upcoming Deadlines - BAX
Werte in diesem Artikel
NEW YORK, Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Baxter and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until December 15, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Baxtersecurities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On July 31, 2025, Baxter announced that it had decided to "voluntarily and temporarily pause shipments and planned installations of the Novum LVP", a medical device used for the controlled delivery of intravenous fluids, and that the Company was "unable to currently commit to an exact timing for resuming shipment and installation for Novum IQ LVPs." Baxter stated that they had offered "customers the option of our Spectrum infusion pump as an alternative" and that the Company's low-end guidance assumes that the Company does not resume shipments for Novum LVPs before the end of the year.
On this news, Baxter's stock price fell $6.29 per share, or 22.4%, to close at $21.76 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-baxter-international-inc--of-class-action-lawsuit-and-upcoming-deadlines---bax-302596689.html
SOURCE Pomerantz LLP
Übrigens: Baxter International und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Baxter International
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Baxter International
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Baxter International Inc.
Analysen zu Baxter International Inc.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 16.10.2018 | Baxter International Underweight | Barclays Capital | |
| 28.07.2017 | Baxter International Neutral | UBS AG | |
| 27.07.2017 | Baxter International Overweight | Barclays Capital | |
| 14.07.2017 | Baxter International Outperform | BMO Capital Markets | |
| 30.06.2017 | Baxter International Overweight | Cantor Fitzgerald |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 27.07.2017 | Baxter International Overweight | Barclays Capital | |
| 14.07.2017 | Baxter International Outperform | BMO Capital Markets | |
| 30.06.2017 | Baxter International Overweight | Cantor Fitzgerald | |
| 11.08.2015 | Baxter International Overweight | Barclays Capital | |
| 10.07.2015 | Baxter International Market Perform | BMO Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 28.07.2017 | Baxter International Neutral | UBS AG | |
| 27.04.2017 | Baxter International Sector Perform | RBC Capital Markets | |
| 26.10.2016 | Baxter International Sector Perform | RBC Capital Markets | |
| 27.04.2016 | Baxter International Sector Perform | RBC Capital Markets | |
| 13.07.2015 | Baxter International Sector Perform | RBC Capital Markets |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 16.10.2018 | Baxter International Underweight | Barclays Capital | |
| 05.10.2011 | Baxter International sell | Citigroup Corp. | |
| 06.10.2005 | Update Baxter International Inc.: Reduce | UBS |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Baxter International Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
